What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P. Petrini P.
. Wu Z, et al. Microbiome. 2021 Sep 7;9(1):184. doi: 10.1186/s40168-021-01115-9. Microbiome. 2021. PMID: 34493333
.
Item in Clipboard
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
